Programmed cell death and survival pathways in prostate cancer cells

Archives of Andrology

Volumn 50, Issue 1, 2004, Pages 27-32

  Lee, E C Y ^a   Tenniswood, M ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Apoptosis; IAP; PTEN; Refractory cancer

Indexed keywords

APOPTOSIS INDUCING FACTOR; HORMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; CANCER CELL; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CELL SURVIVAL; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MORPHOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; STIMULUS RESPONSE;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MALE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 79961205336     PISSN: 01485016     EISSN: None     Source Type: Journal    
DOI: 10.1080/01485010490250498     Document Type: Review

References (29)

1. Baeuerle PA, Baltimore D (1988): I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 242:540-546.
2. Barry MA, Eastman A (1992): Endonuclease activation during apoptosis: the role of cytosolic Ca2+ and pH. Biochem Biophys Res Commun 186:782-789.
3. Bastola DR, Pahwa GS, et al. (2002): Downregulation of PTEN/MMAC/TEP1 expression in human prostate cancer cell line DU145 by growth stimuli. Mol Cell Biochem 236:75-81.
4. Chu ZL, McKinsey TA, et al. (1997): Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci USA 94:10057-10062.
5. Colombel M, Symmans F, et al. (1993): Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone- refractory human prostate cancers. Am J Pathol 143:390-400.
6. Datta SR, Dudek H, et al. (1997): Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-241.
7. Honda T, Kagawa S, et al. (2002): A recombinant adenovirus expressing wild-type Bax induces apoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity. Cancer Biol Ther 1:163-167.
8. Huang H, Cheville JC, et al. (2001): PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem 276:38830-38836.
9. Kimura K, Gelmann EP (2002): Propapoptotic effects of NF-kappaB in LNCaP prostate cancer cells lead to serine protease activation. Cell Death Differ 9:972-980.
10. Kroemer G, Reed JC (2000): Mitochondrial control of cell death. Nat Med 6:513-519.
11. Lee ECY, Zhan P, Schallhorn R, Packman K, Tenniswood M (2003): Antiandrogen-induced cell death in LNCaP human prostate cancer cells. Cell Death Differ 10:761-771.
12. Li J, Yen C, Liaw D, et al. (1997): PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947.
13. Maehama T, Dixon JE (1999): PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol 9:125-128.
14. Marcelli M, Marani M, et al. (2000): Heterogeneous apoptotic responses of prostate cancer cell lines identify an association between sensitivity to staurosporine-induced apoptosis, expression of Bcl-2 family members, and caspase activation. Prostate 42:260-273.
15. McEleny KR, Watson RW, et al. (2002): Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate 51:133-140.
16. Mercurio F, Zhu H, et al. (1997): IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF- kappaB activation. Science 278:860-866.
17. Morris GZ, Williams RL, et al. (2002): Resveratrol induces apoptosis in LNCaP cells and requires hydroxyl groups to decrease viability in LNCaP and DU 145 cells. Prostate 52:319-329.
18. Munshi A, Pappas G, et al. (2001): TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Oncogene 20:3757-3765.
19. Nesterov A, Lu X, et al. (2001): Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 276:10767-10774.
20. Rokhlin OW, Guseva NV, et al. (2002): Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP. Prostate 52:1-11.
21. Rothe M, Pan MG, et al. (1995): The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83:1243-1252.
22. Ruffion A, Al-Sakkaf KA, et al. (2003): The survival effect of prolactin on PC3 prostate cancer cells. Eur Urol 43:301-308.
23. Suh J, Payvandi F, et al. (2002): Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 52:183-200.
24. van Brussel JP, van Steenbrugge GJ, et al. (1999): Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer 35:664-671.
25. Vlietstra RJ, van Alewijk DC, et al. (1998): Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58:2720-2723.
26. Wang CY, Mayo MW, et al. (1998): NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281:1680-1683.
27. Yeh JY, Huang WJ, et al. (2003): Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 54:112-124.
28. Zandi E, Chen Y, Karin M (1998): Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate. Science 281:1360-1363.
29. Zhan P, Lee ECY, et al. (2002): Induction of invasive phenotype by Casodex in hormone sensitive prostate cancer cells. J Steroid Biochem Mol Biol 83:101-111.